DE69232188T2 - Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen - Google Patents

Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen

Info

Publication number
DE69232188T2
DE69232188T2 DE69232188T DE69232188T DE69232188T2 DE 69232188 T2 DE69232188 T2 DE 69232188T2 DE 69232188 T DE69232188 T DE 69232188T DE 69232188 T DE69232188 T DE 69232188T DE 69232188 T2 DE69232188 T2 DE 69232188T2
Authority
DE
Germany
Prior art keywords
steroid
disease conditions
hormone
selective ligands
treating hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232188T
Other languages
English (en)
Other versions
DE69232188D1 (de
Inventor
Ronald M Evans
Richard A Heyman
Christina S Berger
Robert B Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Salk Institute for Biological Studies
Original Assignee
Ligand Pharmaceuticals Inc
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc, Salk Institute for Biological Studies filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69232188D1 publication Critical patent/DE69232188D1/de
Publication of DE69232188T2 publication Critical patent/DE69232188T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
DE69232188T 1991-08-23 1992-08-21 Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen Expired - Fee Related DE69232188T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74876791A 1991-08-23 1991-08-23
PCT/US1992/007064 WO1993003713A1 (en) 1991-08-23 1992-08-21 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones

Publications (2)

Publication Number Publication Date
DE69232188D1 DE69232188D1 (de) 2001-12-13
DE69232188T2 true DE69232188T2 (de) 2002-06-20

Family

ID=25010830

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232188T Expired - Fee Related DE69232188T2 (de) 1991-08-23 1992-08-21 Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen

Country Status (8)

Country Link
US (1) US6096787A (de)
EP (2) EP1120113A3 (de)
JP (1) JPH07505607A (de)
AT (1) ATE208194T1 (de)
AU (1) AU2516092A (de)
CA (1) CA2114936C (de)
DE (1) DE69232188T2 (de)
WO (1) WO1993003713A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
DE69627193T2 (de) 1995-10-06 2004-01-29 Ligand Pharm Inc Dimer-selektive rxr modulatoren und verfahren zu ihrer verwendung
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
FR2802808B1 (fr) * 1999-12-22 2002-08-09 Oreal Utilisation de composes polycycliques aromatiques en tant qu'activateurs des recepteurs de type ppars dans une composition cosmetique ou pharmaceutique
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) * 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
JP4994563B2 (ja) 2001-02-20 2012-08-08 イントレキソン コーポレーション 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
EP1572862B1 (de) * 2001-02-20 2012-08-01 Intrexon Corporation Chimäre retinoid-x-rezeptoren und ihre verwendung in einem neuen induzierbaren genexpressionssystem auf ecdysonrezeptor-basis
DK1373470T3 (da) 2001-02-20 2013-07-29 Intrexon Corp Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem
DE10244149A1 (de) * 2001-09-25 2003-04-30 Werner Keber Verfahren und Einrichtung zum Verhindern einer unzulässigen Flugannäherung von Flugzeugen an zu schützende Bodenobjeke
CA2930389A1 (en) 2001-09-26 2003-04-03 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7563879B2 (en) * 2001-09-26 2009-07-21 Intrexon Corporation Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7304161B2 (en) * 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) * 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) * 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
WO2010032582A1 (ja) * 2008-09-22 2010-03-25 国立大学法人鹿児島大学 成人ｔ細胞白血病治療薬
DK2970106T3 (en) 2013-03-15 2018-08-13 Intrexon Corp CONTAINING DIACYL HYDRAZINES
AU2015317862A1 (en) 2014-09-17 2017-04-06 Intrexon Corporation Boron-containing diacylhydrazine compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3580134D1 (de) * 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem Benzoesaeurederivate.
IL80270A0 (en) * 1985-10-11 1987-01-30 Cird Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method

Also Published As

Publication number Publication date
WO1993003713A1 (en) 1993-03-04
CA2114936C (en) 2004-02-10
EP0600028B1 (de) 2001-11-07
EP0600028A1 (de) 1994-06-08
US6096787A (en) 2000-08-01
ATE208194T1 (de) 2001-11-15
DE69232188D1 (de) 2001-12-13
JPH07505607A (ja) 1995-06-22
CA2114936A1 (en) 1993-03-04
EP1120113A2 (de) 2001-08-01
AU2516092A (en) 1993-03-16
EP1120113A3 (de) 2003-05-07

Similar Documents

Publication Publication Date Title
DE69232188D1 (de) Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen
DE69328981T2 (de) Verfahren zur Behandlung von hyperproliferaktiven Gefässerkrankungen unter Verwendung von Rapamycin, eventuell in Kombination mit Mykophenolsäure
DE68907909D1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE69012261T2 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DE3779346D1 (de) Zusammensetzung zur behandlung der haut.
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE72755T1 (de) Verbaende.
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE69200684T2 (de) Vorrichtung zur thermischen Behandlung von laufenden Garnen.
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE3782214T2 (de) Mittel zur behandlung des scheidenmilieus.
DE3650505T2 (de) AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE3786895D1 (de) Bleichfixierloesung mit einer guten behandlungswirkung und verfahren zur behandlung eines lichtempfindlichen materials, das diese verwendet.
DE3861764D1 (de) Verfahren und vorrichtung zur diskontinuierlichen nassbehandlung von gestricktem oder gewirktem textilgut.
DE69004529T2 (de) Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
ATE110961T1 (de) Behandlung von beatmungsabhängigkeit mit wachstumshormon.
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
DE3768042D1 (de) Maschine zur behandlung von photographischen filmen.
DE69219039D1 (de) Verwendung von Felbamate zur Herstellung eines Arzneimittels zur Behandlung neuropsychopharmakologischer Störungen
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee